OncoMatch/Clinical Trials/NCT06904183
Lenvatinib, Sintilimab, and DEB-TACE With/Without HAIC for HCC >7 cm With PVTT
Is NCT06904183 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including LEN+SIN+DEB-TACE+HAIC and LEN+SIN+DEB-TACE for hepatocellular carcinoma non-resectable.
Treatment: LEN+SIN+DEB-TACE+HAIC · LEN+SIN+DEB-TACE — This study is conducted to evaluate the efficacy and safety of lenvatinib plus sintilimab, transarterial chemoembolization (TACE) with drug-eluting beads (DEB-TACE) and hepatic artery infusion chemotherapy (HAIC) with FOLFOX regemen (LEN+SIN+DEB-TACE+HAIC) versus lenvatinib plus sintilimab and DEB-TACE (LEN+SIN+DEB-TACE) for large hepatocellular carcinoma (\> 7cm) with portal vein tumor thrombosis (PVTT).
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Hepatocellular Carcinoma
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Cannot have received: transarterial chemoembolization
previous treatment with TACE
Cannot have received: hepatic arterial infusion chemotherapy
previous treatment with HAIC
Cannot have received: transarterial embolization
previous treatment with TAE
Cannot have received: radiation therapy
previous treatment with radiotherapy
Cannot have received: systemic therapy
previous treatment with systemic therapy
Lab requirements
Blood counts
leukocyte count >3.0×10^9/L, neutrophil count >1.5×10^9/L, platelet count ≥75×10^9/L, hemoglobin 85 g/L
Kidney function
creatinine clearance rate ≤1.5×upper limit of the normal
Liver function
alanine transaminase and aspartate transaminase ≤5×upper limit of the normal; prothrombin time prolongation ≤4 seconds; Child-Pugh class A/B
Cardiac function
organ (heart and kidneys) dysfunction, unable to tolerate TACE or HAIC treatment [excluded]
adequate hematologic and organ function, with leukocyte count>3.0×10^9/L, neutrophil count>1.5×10^9/L, platelet count≥75×10^9/L, hemoglobin 85 g/L, alanine transaminase and aspartate transaminase≤5×upper limit of the normal, creatinine clearance rate≤1.5×upper limit of the normal; prothrombin time prolongation ≤4 seconds; Child-Pugh class A/B; organ (heart and kidneys) dysfunction, unable to tolerate TACE or HAIC treatment [excluded]
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06904183 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages